--- title: Tardive Dyskinesia Market Opportunities: Emerging Drugs... description: The tardive dyskinesia (TD) therapeutics market was valued at approximately USD 4,400 million across 7 major markets in 2025 and is projected to reach USD... canonical: https://daily.dev/posts/tardive-dyskinesia-market-opportunities-emerging-drugs-and-strategic-insights-m1nfmvhuc twitter:card: summary_large_image twitter:site: @dailydotdev og:type: website og:site_name: daily.dev og:title: Tardive Dyskinesia Market Opportunities: Emerging Drugs and Strategic Insights | daily.dev og:description: The tardive dyskinesia (TD) therapeutics market was valued at approximately USD 4,400 million across 7 major markets in 2025 and is projected to reach USD... og:url: https://daily.dev/posts/tardive-dyskinesia-market-opportunities-emerging-drugs-and-strategic-insights-m1nfmvhuc og:image: https://api.daily.dev/og/posts/m1NFMvhuc.png og:image:alt: Tardive Dyskinesia Market Opportunities: Emerging Drugs and Strategic Insights og:image:width: 1200 og:image:height: 630 og:locale: en --- [](https://daily.dev/kanishkkumar)[Kanishk Kumar @kanishkkumar • Aug 0410](https://daily.dev/kanishkkumar) # Tardive Dyskinesia Market Opportunities: Emerging Drugs and Strategic Insights Comment Bookmark Copy Share your thoughts Post [](https://daily.dev/kanishkkumar) [Kanishk Kumar](https://daily.dev/kanishkkumar) [@kanishkkumar](https://daily.dev/kanishkkumar) Joined Dec 2\. 2025 10 #### Would you recommend this post? Copy link WhatsApp Facebook X New Squad Copy linkShare with your friends ```json {"@context":"https://schema.org","@graph":[{"@type":"Organization","@id":"https://daily.dev/#organization","name":"daily.dev","url":"https://daily.dev","logo":{"@type":"ImageObject","url":"https://daily.dev/apple-touch-icon.png","width":180,"height":180},"sameAs":["https://twitter.com/dailydotdev","https://github.com/dailydotdev","https://www.linkedin.com/company/daily-dev-ltd"]},{"@type":"WebSite","@id":"https://daily.dev/#website","url":"https://daily.dev","name":"daily.dev","publisher":{"@id":"https://daily.dev/#organization"},"potentialAction":{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https://daily.dev/search?q={search_term_string}"},"query-input":"required name=search_term_string"}}]} {"@context":"https://schema.org","@type":"DiscussionForumPosting","mainEntityOfPage":"https://daily.dev/posts/tardive-dyskinesia-market-opportunities-emerging-drugs-and-strategic-insights-m1nfmvhuc","headline":"Tardive Dyskinesia Market Opportunities: Emerging Drugs and Strategic Insights","text":"The tardive dyskinesia (TD) therapeutics market was valued at approximately USD 4,400 million across 7 major markets in 2025 and is projected to reach USD 10,600 million by 2036 at an 8.1% CAGR. The US dominates with nearly 98% of total revenue, driven by earlier drug launches and established reimbursement. Two VMAT2 inhibitors — valbenazine (INGREZZA) and deutetrabenazine (AUSTEDO) — define the current standard of care. The pipeline remains thin, with most candidates in Phase I/II, including Neurocrine's NBI-1065890, SOM Biotech's SOM3355, and Acadia's ACP-2712. Persistent underdiagnosis and limited specialist access suggest significant untapped market potential.","url":"https://daily.dev/posts/tardive-dyskinesia-market-opportunities-emerging-drugs-and-strategic-insights-m1nfmvhuc","datePublished":"2026-08-04T16:01:19.509Z","dateModified":"2026-08-04T16:01:40.310Z","author":{"@type":"Person","name":"Kanishk Kumar","url":"https://daily.dev/kanishkkumar","image":"https://lh3.googleusercontent.com/a/ACg8ocLDQ7ARhfM9C12NZ9I4vp_IAiM5GY1PNNLoRTqsKnyJhX8SC6e3=s96-c","interactionStatistic":{"@type":"InteractionCounter","interactionType":{"@type":"EndorseAction"},"userInteractionCount":10}},"interactionStatistic":[{"@type":"InteractionCounter","interactionType":{"@type":"LikeAction"},"userInteractionCount":0},{"@type":"InteractionCounter","interactionType":{"@type":"CommentAction"},"userInteractionCount":0}],"isPartOf":{"@type":"WebPage","url":"https://daily.dev/sources/qt0b9kzh0zvlkb8rocnuf","name":"Kanishk Kumar"}} {"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://daily.dev"},{"@type":"ListItem","position":2,"name":"Kanishk Kumar","item":"https://daily.dev/sources/qt0b9kzh0zvlkb8rocnuf"},{"@type":"ListItem","position":3,"name":"Tardive Dyskinesia Market Opportunities: Emerging Drugs and Strategic Insights"}]} ```